Fluconazole: Clinical Trials

35 trials of Fluconazole, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed, 3 terminated, 3 unknown, 2 recruiting. 35 Phase 2, 6 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 235Completed 26, Terminated 3, Unknown 3, Recruiting 2, Withdrawn 1
Phase 36Completed 2, Unknown 2, Recruiting 1, Terminated 1
Phase 14Completed 3, Withdrawn 1

Follow Fluconazole: new trials by email Literature Review of Fluconazole trials Research Report on Fluconazole

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients
WXSH0102/placebo, fluconazole capsules/placebo - Vaginitis
Phase 2RecruitingCisen Pharmaceutical CO., LTD.1082025-01-132025-02-13
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
Chlorhexidine Gluconate, Fluconazole - Candidiasis, Vulvovaginal
Phase 2UnknownKarolinska Institutet602022-04-272022-05-20
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
Fluconazole, Placebo - Nephrolithiasis, Nephrocalcinosis
Phase 2CompletedHospices Civils de Lyon562021-01-132024-07-12
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis
Phase 2 / Phase 3UnknownProFem GmbH4322019-10-012022-09-22
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
Single dose liposomal Amphotericin and Fluconazole, Fluconazole - Cryptococcal Meningitis
Phase 2 / Phase 3RecruitingMakerere University3562019-06-202026-04-28
Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Vancomycin, Neomycin, Ciprofloxacin - Crohn Disease
Phase 2CompletedChildren's Hospital of Philadelphia102018-07-122022-02-09
Treatment With Tamoxifen in Cryptococcal Meningitis
Tamoxifen, Amphotericin B, Fluconazole - Meningitis Streptococcal, Hiv
Phase 2CompletedOxford University Clinical Research Unit, Vietnam502017-10-102019-12-02
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Fluconazole, SCY-078 - Candida Vulvovaginitis
Phase 2CompletedScynexis, Inc.1862017-08-012021-08-12
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
F901318 with fluconazole low dose, F901318 with fluconazole high dose, F901318 with posaconazole - Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnF2G Ltd2017-03-012018-02-15
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection
Phase 2CompletedMatinas BioPharma Nanotechnologies, Inc.1372016-11-012018-11-02
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Fluconazole, Vancomycin, Neomycin - Crohn's Disease
Phase 2CompletedUniversity of Pennsylvania82016-08-012024-02-06
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
CD101, Caspofungin, Fluconazole - Candidemia, Mycoses
Phase 2CompletedCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2072016-07-262020-12-08
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%) - Candidiasis, Vulvovaginal, Mycoses
Phase 2CompletedCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1262016-06-082020-08-31
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
SCY-078, Fluconazole - Vulvovaginal Candidiasis
Phase 2CompletedScynexis, Inc.962015-11-012019-07-12
Fluconazole Versus Micafungin in Neonates With Candidiasis
Fluconazole, Micafungin - Candidiasis
Phase 2 / Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France1002014-10-012025-09-04
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive
Phase 2CompletedScynexis, Inc.272014-09-012024-06-25
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
Zinc Sulfate Oral Product, Levofloxacin 500Mg Oral Tablet, Fluconazole 200mg tab - Stem Cell Transplant Complications
Phase 2CompletedAzienda Ospedaliero, Universitaria Pisana202014-01-012020-01-07
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Flucytosine and fluconazole, Fluconazole - Cryptococcal Infection Disseminated
Phase 2TerminatedYale University62013-09-012021-09-29
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
VT-1161, Fluconazole - Candidiasis, Vulvovaginal
Phase 2CompletedViamet552013-08-012018-08-01
Pharmacokinetic Study of Fluconazole in Premature Infants
Fluconazole - Very Low Birth Weight Infant
Phase 2CompletedSeoul National University Hospital802012-09-012014-11-19

Showing 20 of 35. Sign in to see all of them.

Conditions studied

Candidiasis, Vulvovaginal (7)  ·  Meningitis, Cryptococcal (7)  ·  HIV Infections (6)  ·  Mycoses (6)  ·  Crohn Disease (3)  ·  Meningitis (3)  ·  AIDS-Related Opportunistic Infections (2)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Candidemia (2)  ·  Candidiasis (2)  ·  Candidiasis, Invasive (2)  ·  Cryptococcosis (2)  ·  Rare Diseases (2)  ·  Sporotrichosis (2)  ·  Vulvovaginitis (2)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Scynexis, Inc. (3)  ·  Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Azienda Ospedaliero, Universitaria Pisana (1)  ·  Children's Hospital of Philadelphia (1)  ·  Cisen Pharmaceutical CO., LTD. (1)  ·  Emory University (1)  ·  F2G Ltd (1)  ·  Hospices Civils de Lyon (1)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)  ·  InterMune (1)  ·  Johns Hopkins University (1)  ·  Karolinska Institutet (1)  ·  Makerere University (1)

Countries

United States (17)  ·  France (4)  ·  Belgium (3)  ·  Italy (3)  ·  Spain (3)  ·  Thailand (3)  ·  Canada (2)  ·  Dominican Republic (2)  ·  Germany (2)  ·  Guatemala (2)  ·  Honduras (2)  ·  Kenya (2)  ·  Peru (2)  ·  South Africa (2)  ·  Uganda (2)

Top investigators

David Angulo, MD (3)  ·  Lindsey Albenberg, DO (2)  ·  William Dismukes (2)  ·  Alena Jandourek, MD (1)  ·  Ana-Claire L Meyer, MD, MSHS (1)  ·  Arnold M. Markoe, MD, ScD (1)  ·  Arshed A Quyyumi, MD (1)  ·  Cathrin Alvendal, MD, PhD (1)  ·  David N Herndon, MD (1)  ·  Douglas Kling (1)  ·  Han-Suk Kim, MD, PhD (1)  ·  Herbert Kiss, Prof. (1)  ·  J Jacobson (1)

Results publications

PMID 16505648, PMID 19172247, PMID 19441980, PMID 19734776, PMID 19897055, PMID 20881067, PMID 21555712, PMID 22463890, PMID 22606232, PMID 22895351, PMID 23150682, PMID 23303450, PMID 24009246, PMID 24298851, PMID 24655871, PMID 24675657, PMID 24824900, PMID 24918945, PMID 24925526, PMID 25211297, PMID 25514427, PMID 25648989, PMID 25807408, PMID 27171844, PMID 27433905, PMID 28240622, PMID 29744900, PMID 29747074, PMID 30801037, PMID 30910892, PMID 32818963, PMID 32955088, PMID 33922391, PMID 34555149, PMID 34581270, PMID 35710560, PMID 36396498, PMID 36780493, PMID 38008099, PMID 38502709, PMID 39044381, PMID 39468640, PMID 39529079, PMID 40970688, PMID 41845293, PMID 41940006

NIH funding

2008 (1), 2015 (1), K23DK109136 (1), P30MH075673 (1), P50GM060338 (1), R01HL079115 (1), R21NS077858 (1)